A new injectable body contouring product called alloClae is attracting growing attention in the U.S.because it is made from donated human fat obtained from cadaver tissue.

Developed by Tiger Aesthetics, the product is marketed as an alternative to traditional fat grafting procedures, allowing physicians to restore volume in areas such as the breasts, buttocks, face, and other parts of the body without liposuction or major surgery.

Doctors report increasing interest, particularly among patients who have lost significant weight while taking GLP-1 medications such as Ozempic and Wegovy and want to restore volume in specific areas.

Although similar products such as Renuva have existed for years, alloClae offers larger injection volumes, making it suitable for broader body contouring applications.The treatment can cost tens of thousands of dollars depending on the amount injected.The article also examines ethical and regulatory concerns surrounding the use of donated human tissue.

While Tiger Aesthetics says donors provide informed consent through accredited tissue banks and that donor DNA is removed during processing, bioethicists question whether for-profit cosmetic uses align with the altruistic intentions of body donation.

Regulatory scrutiny has also emerged, with New York health authorities denying the company's tissue bank license application, leading Tiger Aesthetics to file a lawsuit challenging the decision.

The story includes patient experiences ranging from satisfaction with cosmetic results to complications such as fat necrosis, which may require additional medical treatment.

Plastic surgeons emphasize that long-term clinical data comparing alloClae with conventional fat grafting remain limited, leaving questions about long-term safety and effectiveness despite growing commercial interest.